PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Linda R. Duska, MD, MPH - Chair’s Take on Advances in Gynecologic Cancer Care: Exploring New Advances and Innovative Therapies in Endometrial and Cervical Cancers
Go online to PeerView.com/VSK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Watch Dr. Duska provide a brief recap of recent developments in endometrial and cervical cancer management, including evidence presented at the 2020 American Society of Clinical Oncology Annual Meeting. Dr. Duska comments on these findings and offers thoughts on new and emerging strategies, including targeted, immune checkpoint inhibitor, antibody-based, and combination therapies, in different patient populations with gynecologic cancer. Upon completion of this activity, participants should be better able to: Summarize the current treatment role of novel therapeutics, including in conjunction with modern molecular diagnostic testing, in gynecologic cancers, Describe updated evidence on new and emerging strategies, including targeted, immune checkpoint inhibitor, antibody-based, and combination therapies, in different patient populations with gynecologic cancers, Integrate approved and emerging options in the management of endometrial and cervical cancer, including in the context of clinical trials, based on disease characteristics and latest recommendations, Discuss the spectrum of unique safety considerations with novel targeted, antibody-based, and immunotherapy regimens in patients with gynecologic cancers.